Galectin Therapeutics (GALT) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Q32 Bio (QTTB) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 317.0% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -91.1% for QTTB. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $249.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | QTTB |
|---|---|---|
| Share price | $2.69 | $8.34 |
| Market cap | $271.35M | $249.57M |
| 1-day change | -4.27% | -1.65% |
| YTD return | -35.34% | +151.20% |
| 1-year return | -49.72% | +317.00% |
| 5-year return | +4.67% | -91.12% |
| P/E ratio (TTM) | — | 2.32 |
| EPS (TTM) | $-0.32 | $3.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $53.74M |
| Net income (latest FY) | $-30.84M | $29.82M |
| Operating margin | — | 31.45% |
| Net margin | — | 55.49% |
| 52-week high | $7.13 | $23.57 |
| 52-week low | $2.03 | $1.98 |
| Distance from 52-week high | -62.27% | -64.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +375.66% |
| Average volume | 252.31K | 692.58K |
| Shares outstanding | 100.88M | 29.92M |
| Employees | 9 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed GALT by 366.7 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
GALT vs QTTB FAQ
Which is bigger, Galectin Therapeutics or Q32 Bio?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $249.57M for Q32 Bio (QTTB).
Which stock has performed better over the past year, GALT or QTTB?
QTTB returned +317.00% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.